Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK4. It shows promise in cancer therapy by blocking cell cycle progression in tumor cells. The compound has been studied for its antiproliferative effects in various cancer cell lines, including breast, lung, and leukemia models. Its mechanism involves binding to the ATP-binding site of CDKs, thereby preventing phosphorylation of key regulatory proteins. Due to its ability to induce cell cycle arrest and apoptosis, it serves as a lead compound in the development of targeted oncology drugs. Also used as a biochemical tool to study cell cycle dynamics and kinase signaling pathways in vitro.